
Eric Blount
Examiner (ID: 14763, Phone: (571)272-2973 , Office: P/2684 )
| Most Active Art Unit | 2684 |
| Art Unit(s) | 2684, 2612, 2636, 2685 |
| Total Applications | 1590 |
| Issued Applications | 1210 |
| Pending Applications | 89 |
| Abandoned Applications | 303 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16869976
[patent_doc_number] => 20210163443
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => Febrifugine Derivatives
[patent_app_type] => utility
[patent_app_number] => 17/108024
[patent_app_country] => US
[patent_app_date] => 2020-12-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15819
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17108024
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/108024 | Febrifugine Derivatives | Nov 30, 2020 | Abandoned |
Array
(
[id] => 18117489
[patent_doc_number] => 11548870
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-10
[patent_title] => Compounds useful as inhibitors of helios protein
[patent_app_type] => utility
[patent_app_number] => 16/950978
[patent_app_country] => US
[patent_app_date] => 2020-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25363
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 341
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950978
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/950978 | Compounds useful as inhibitors of helios protein | Nov 17, 2020 | Issued |
Array
(
[id] => 16673048
[patent_doc_number] => 20210061811
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/096026
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096026
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/096026 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | Nov 11, 2020 | Issued |
Array
(
[id] => 18117490
[patent_doc_number] => 11548871
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-10
[patent_title] => Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/096150
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46850
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 258
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096150
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/096150 | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof | Nov 11, 2020 | Issued |
Array
(
[id] => 16885348
[patent_doc_number] => 20210171543
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => MCL1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/094447
[patent_app_country] => US
[patent_app_date] => 2020-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84796
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17094447
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/094447 | MCL1 inhibitors | Nov 9, 2020 | Issued |
Array
(
[id] => 20593537
[patent_doc_number] => 12577239
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-17
[patent_title] => Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds
[patent_app_type] => utility
[patent_app_number] => 17/775979
[patent_app_country] => US
[patent_app_date] => 2020-11-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48558
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 642
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775979
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/775979 | Sulfilimines or sulfoximines containing fungicidal heterocyclic compounds | Nov 9, 2020 | Issued |
Array
(
[id] => 18153047
[patent_doc_number] => 11566007
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-31
[patent_title] => Ras inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/089035
[patent_app_country] => US
[patent_app_date] => 2020-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 9
[patent_no_of_words] => 94713
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089035
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/089035 | Ras inhibitors | Nov 3, 2020 | Issued |
Array
(
[id] => 16621440
[patent_doc_number] => 20210040093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => DEGRADATION OF CYCLIN-DEPENDENT KINASE 8 (CDK8) BY CONJUGATION OF CDK8 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/083940
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27527
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17083940
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/083940 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | Oct 28, 2020 | Issued |
Array
(
[id] => 17198730
[patent_doc_number] => 20210338824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/083172
[patent_app_country] => US
[patent_app_date] => 2020-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69042
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17083172
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/083172 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Oct 27, 2020 | Issued |
Array
(
[id] => 20108166
[patent_doc_number] => 12358872
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-15
[patent_title] => Method for producing laurolactam, device for synthesizing same, laurolactam composition produced thereby, and method for producing polylaurolactam using same
[patent_app_type] => utility
[patent_app_number] => 17/782244
[patent_app_country] => US
[patent_app_date] => 2020-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17782244
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/782244 | Method for producing laurolactam, device for synthesizing same, laurolactam composition produced thereby, and method for producing polylaurolactam using same | Oct 26, 2020 | Issued |
Array
(
[id] => 17742574
[patent_doc_number] => 11390631
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-07-19
[patent_title] => Benzodiazepine derivatives as RSV inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/081289
[patent_app_country] => US
[patent_app_date] => 2020-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 73201
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17081289
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/081289 | Benzodiazepine derivatives as RSV inhibitors | Oct 26, 2020 | Issued |
Array
(
[id] => 17742576
[patent_doc_number] => 11390633
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-19
[patent_title] => Methods of preparing cytotoxic benzodiazepine derivatives
[patent_app_type] => utility
[patent_app_number] => 17/077688
[patent_app_country] => US
[patent_app_date] => 2020-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 12902
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 260
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17077688
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/077688 | Methods of preparing cytotoxic benzodiazepine derivatives | Oct 21, 2020 | Issued |
Array
(
[id] => 17096844
[patent_doc_number] => 20210284635
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => NOVEL NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ARRHYTHMIA
[patent_app_type] => utility
[patent_app_number] => 17/071311
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071311
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071311 | Naphthyridinone derivatives and their use in the treatment of arrhythmia | Oct 14, 2020 | Issued |
Array
(
[id] => 16792951
[patent_doc_number] => 20210122768
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-29
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/060611
[patent_app_country] => US
[patent_app_date] => 2020-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17060611
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/060611 | Methods of preparing cytotoxic benzodiazepine derivatives | Sep 30, 2020 | Issued |
Array
(
[id] => 17742563
[patent_doc_number] => 11390620
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-19
[patent_title] => Polymorphic forms of metopimazine
[patent_app_type] => utility
[patent_app_number] => 17/036969
[patent_app_country] => US
[patent_app_date] => 2020-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 24526
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 67
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17036969
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/036969 | Polymorphic forms of metopimazine | Sep 28, 2020 | Issued |
Array
(
[id] => 19090914
[patent_doc_number] => 11952344
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-09
[patent_title] => Heterocyclic compound and use thereof
[patent_app_type] => utility
[patent_app_number] => 17/754118
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22012
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 316
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754118
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/754118 | Heterocyclic compound and use thereof | Sep 24, 2020 | Issued |
Array
(
[id] => 16613580
[patent_doc_number] => 20210032233
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => Inhibitors of Beta-Hydroxylase for Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 17/029127
[patent_app_country] => US
[patent_app_date] => 2020-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24077
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 138
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17029127
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/029127 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | Sep 22, 2020 | Abandoned |
Array
(
[id] => 17556045
[patent_doc_number] => 11312721
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
[patent_app_type] => utility
[patent_app_number] => 17/028917
[patent_app_country] => US
[patent_app_date] => 2020-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 70233
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 489
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17028917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/028917 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | Sep 21, 2020 | Issued |
Array
(
[id] => 18700041
[patent_doc_number] => 11786527
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Pharmaceutical composition and preparation method therefor and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/022590
[patent_app_country] => US
[patent_app_date] => 2020-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 16
[patent_no_of_words] => 15272
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17022590
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/022590 | Pharmaceutical composition and preparation method therefor and uses thereof | Sep 15, 2020 | Issued |
Array
(
[id] => 17945708
[patent_doc_number] => 20220332725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/023266
[patent_app_country] => US
[patent_app_date] => 2020-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17023266
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/023266 | Compounds for the treatment of cancer and inflammatory disease | Sep 15, 2020 | Issued |